Employers › Verrica Pharmaceuticals
Recordkeeping fees per participant · Verrica Pharmaceuticals 401(k) · plan year 2024
$123.50
Higher than 70% of the 7,477 plans $1 to 10M that report it.
= $20,377 / 165
Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251014094930NAL0001187283001, received 2025-10-14
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251014094930NAL0001187283001, received 2025-10-14
Percentiles compare this plan with the Schedule H plans $1 to 10M in assets of the same plan year, excluding final filings; shown only where at least 50 comparable plans report the figure. Plan year 2024-01-01 to 2024-12-31, filing received 2025-10-14.
Administrative expenses excluding investment management, per participant
$123.50
Higher than 57% of the 14,713 plans $1 to 10M that report it.
= $20,377 / 165
derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251014094930NAL0001187283001, received 2025-10-14
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251014094930NAL0001187283001, received 2025-10-14
Administrative expenses per participant
$123.50
Higher than 43% of the 15,210 plans $1 to 10M that report it.
= $20,377 / 165
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251014094930NAL0001187283001, received 2025-10-14
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251014094930NAL0001187283001, received 2025-10-14
Administrative expenses as a share of assets
0.354%
Higher than 35% of the 15,243 plans $1 to 10M that report it.
= $20,377 / $5,751,698
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251014094930NAL0001187283001, received 2025-10-14
assets_eoy: Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251014094930NAL0001187283001, received 2025-10-14
Employer contributions per participant
$4,779
Higher than 98% of the 13,342 plans $1 to 10M that report it.
= $788,471 / 165
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251014094930NAL0001187283001, received 2025-10-14
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251014094930NAL0001187283001, received 2025-10-14
Employer share of total contributions
22.9%
Higher than 31% of the 13,370 plans $1 to 10M that report it.
= $788,471 / $3,450,494
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251014094930NAL0001187283001, received 2025-10-14
total_contrib: Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251014094930NAL0001187283001, received 2025-10-14
Plan terms are described in Verrica Pharmaceuticals Inc.'s SEC filings: Form 10-K filed 2026-03-11. No term could be quoted from them with the required precision.
2E profit-sharing · 2F ERISA 404(c) plan · 2G fully participant-directed · 2J 401(k) feature · 2K 401(m) arrangement · 2S pre-approved plan document · 2T default investment (QDIA) · 3D IRS pre-approved plan · Form 5500, line 8a; TYPE_PENSION_BNFT_CODE pos 81; filing 20251014094930NAL0001187283001, received 2025-10-14
| Field | Value | Source |
|---|---|---|
| Plan sponsor | VERRICA PHARMACEUTICALS | Form 5500, Part II line 2a; SPONSOR_DFE_NAME pos 19; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Plan name | VERRICA PHARMACEUTICALS 401(K) | Form 5500, line 1a; PLAN_NAME pos 16; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Sponsor EIN / plan number | 46-3137900 / 001 | Form 5500, line 2b; SPONS_DFE_EIN pos 44; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Plan type | single-employer | Form 5500, Part I line A; TYPE_PLAN_ENTITY_CD pos 4; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Sponsor location | WEST CHESTER, PA | Form 5500, line 2a; SPONS_DFE_MAIL_US_STATE pos 25; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Industry (business code) | 325410, Manufacturing | Form 5500, line 2d; BUSINESS_CODE pos 46; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Plan year | 2024-01-01 to 2024-12-31 | Form 5500, Part I plan year; FORM_PLAN_YEAR_BEGIN_DATE pos 2; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Filing received | 2025-10-14 | Form 5500, EFAST2 receipt date; DATE_RECEIVED pos 102; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Final filing | no | Form 5500, Part I line B; FINAL_FILING_IND pos 8; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Amended filing | no | Form 5500, Part I line B; AMENDED_IND pos 7; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Participants, beginning of year | 141 | Form 5500, line 5; TOT_PARTCP_BOY_CNT pos 71; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Active participants | 102 | Form 5500, line 6a(2); TOT_ACTIVE_PARTCP_CNT pos 72; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Participants, end of year | 176 | Form 5500, line 6f; TOT_ACT_RTD_SEP_BENEF_CNT pos 77; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Participants with an account balance | 165 | Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Total assets, beginning of year | $3,916,811 | Schedule H, Part I line 1f col (a); TOT_ASSETS_BOY_AMT pos 30; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Total assets, end of year | $5,751,698 | Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Net assets, end of year | $5,751,698 | Schedule H, line 1l col (b); NET_ASSETS_EOY_AMT pos 67; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Total income | $4,069,096 | Schedule H, Part II line 2d; TOT_INCOME_AMT pos 97; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Net income | $1,834,887 | Schedule H, line 2k; NET_INCOME_AMT pos 111; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Employer contributions | $788,471 | Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Participant contributions | $1,489,690 | Schedule H, line 2a(1)(B); PARTICIPANT_CONTRIB_AMT pos 69; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Other contributions (incl. rollovers) | $1,172,333 | Schedule H, line 2a(1)(C); OTH_CONTRIB_RCVD_AMT pos 70; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Total contributions | $3,450,494 | Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Benefit payments | $2,212,436 | Schedule H, line 2e(4); TOT_DISTRIB_BNFT_AMT pos 101; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Total expenses (incl. benefit payments) | $2,234,209 | Schedule H, line 2j; TOT_EXPENSES_AMT pos 110; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Total administrative expenses | $20,377 | Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Recordkeeping fees | $20,377 | Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Administrative expenses excluding investment management | $20,377 | derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Held in common/collective trusts | $32,454 | Schedule H, line 1c(9) col (b); INT_COMMON_TR_EOY_AMT pos 51; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Held in mutual funds | $5,718,642 | Schedule H, line 1c(13) col (b); INT_REG_INVST_CO_EOY_AMT pos 55; filing 20251014094930NAL0001187283001, received 2025-10-14 |
| Independent auditor | FISCHER CUNNANE & ASSOCIATES LTD | Schedule H, Part III line 3a; ACCOUNTANT_FIRM_NAME pos 116; filing 20251014094930NAL0001187283001, received 2025-10-14 |
Position = column in the DOL layout for form year 2024. Filing 20251014094930NAL0001187283001, received 2025-10-14.
| Provider | Relationship | Service codes | Direct compensation | Indirect |
|---|---|---|---|---|
| EQUITY SERVICES INC | INVESTMENT ADVISOR | 27 Investment advisory (plan); 51 Investment management fees paid directly by plan; 28 Investment management; 70 Consulting fees; 16 Consulting (general); 26 Investment advisory (participants) | $13,267 | no |
| ATLANTIC PENSION SERVICES INC | PLAN ADMINISTRATOR | 13 Contract administrator; 14 Plan administrator; 63 Distribution (12b-1) fees | $4,000 | no |
| THE VANGUARD GROUP INCrecordkeeper | RECORD KEEPER | 15 Recordkeeping and information management | $3,810 | no |
Schedule C Part I line 2: name (a), service codes (b), relationship (c), direct compensation paid by the plan (d), indirect compensation received (e). Filing 20251014094930NAL0001187283001, received 2025-10-14.
| Figure | 2023 | 2024 | Change |
|---|---|---|---|
| Total assets | $3,916,811 | $5,751,698 | 46.8% |
| Participants with a balance | 133 | 165 | 24.1% |
| Administrative expenses | $6,086 | $20,377 | 234.8% |
| Recordkeeping fees per participant | not reported | $123.50 | |
| Employer contributions | $426,389 | $788,471 | 84.9% |
Prior filing 20240701100212NAL0007703602001, received 2024-07-01; the plan years are contiguous.
Sponsor name as filed: VERRICA PHARMACEUTICALS; SEC registrant: Verrica Pharmaceuticals Inc. (CIK 1660334, matched by EIN; display name from the Form 10-K cover).